Nicotinamide-d3

Nicotinamide-d3 (Niacinamide-d3) is deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM) . Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity[1][2][3][4].

Product Specifications

CAS Number

[2162970-00-3]

Product Name Alternative

Niacinamide-d3; Nicotinic acid amide-d3

UNSPSC

12352005

Target

Endogenous Metabolite; HBV; Isotope-Labeled Compounds; Organoid; Sirtuin

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Others; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(N)C1=C(C([2H])=C(N=C1)[2H])[2H]

Molecular Formula

C6H3D3N2O

Molecular Weight

125.14

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Hwang ES, et al. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell Mol Life Sci. 2017 Sep;74 (18) :3347-3362. |[3]Li WY, et al. The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo. Arch Virol. 2016 Mar;161 (3) :621-30. |[4]Zhang Y, et al. Nicotinamide promotes pancreatic differentiation through the dual inhibition of CK1 and ROCK kinases in human embryonic stem cells. Stem Cell Res Ther. 2021 Jun 25;12 (1) :362. |[5][1] Francesca Scatozza, et al. Nicotinamide inhibits melanoma in vitro and in vivo. J Exp Clin Cancer Res. 2020 Oct 7;39 (1) :211.